TOSHIBA/UT-FORTEM
22.3.2021 23:02:06 CET | Business Wire | Press release
Toshiba Corporation (TOKYO:6502) today announced that Toshiba Infrastructure Systems & Solutions Corporation, the Toshiba Group company specializing in the global infrastructure business (hereinafter Toshiba), has entered into a strategic business alliance with Fortem Technologies, Inc. (hereafter Fortem), and invested 15 million USD in the company. Fortem is a technology leader in counter-drone security and Toshiba, through the alliance, aims to expand its radar-based security solutions business.
Based in Utah, US, Fortem is a drone security company that has grown rapidly in recent years by supplying leading counter-drone systems, notably highly accurate small drone detection radars that are easily installed, and autonomous drones that can capture rogue drones in a net.
“Toshiba is a world-renowned technical and sales powerhouse,” said Timothy Bean, CEO of Fortem. “We are very pleased to announce this alliance to accelerate the delivery of solutions to our customers that combine the disruptive innovation of our AI-enabled Fortem SkyDome System with the depth of Toshiba’s commercial drone RF detection expertise and advanced radar technology. This partnership brings added confidence to security professionals who must secure the airspace above their venues, campuses and metro regions.”
Toshiba has already commercialized a drone detection system that plots incoming direction and altitude from radio waves emitted by the drone in flight. Toshiba is also strengthening its drone security business through research and development of related products.
The alliance will integrate Toshiba and Fortem’s highly complementary systems to realize more effective, multi-layered counter-drone solutions and services, and expand sales in Japan and the US, and in promising overseas markets, including those of Asia, Europe, the Middle East, with mutual access to each other’s sales network.
Masaki Haruyama, Vice President of Toshiba said, “We are excited to partner with Fortem, a pioneering counter-drone solution provider with proven detection system and unique and highly effective interception system. Toshiba has a long history of providing leading technologies of radars. With the perfectly complementary technologies and products of the two companies, we are confident that we can become a global top-tier player in a rapidly growing market, and contribute a safer, more reliable facilities.
Going forward, Toshiba will contribute to ensuring infrastructure security through the alliance with Fortem, by responding to the growing need to prevent damage caused by suspicious drones at airports and other critical facilities, stadiums and other large venues, and private properties around the world. Toshiba aims to win annual sales of 30 billion JPY in the counter-drone security business by FY2030.
About Fortem Technologies, Inc.
- Founded: 2016
- Representative: Timothy Bean
- Headquarters: Utah, the United States
- Employees: Over 100 people
- Business: Counter-drone security products and services
About Toshiba Corporation
Toshiba Corporation leads a global group of companies that combines knowledge and capabilities from over 140 years of experience in a wide range of businesses—from energy and social infrastructure to electronic devices—with world-class capabilities in information processing, digital and AI technologies. These distinctive strengths support Toshiba’s continued evolution toward becoming an Infrastructure Services Company that promotes data utilization and digitization, and one of the world’s leading cyber-physical-systems technology companies. Guided by the Basic Commitment of the Toshiba Group, “Committed to People, Committed to the Future,” Toshiba contributes to society’s positive development with services and solutions that lead to a better world. The Group and its 130,000 employees worldwide secured annual sales surpassing 3.4 trillion yen in FY2019.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210322005284/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 11:47:00 CEST | Press release
The program has involved over 1,100 startups across 50+ countries, delivering 26 pilot projects. Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food prod
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 10:16:00 CEST | Press release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom